BridgeMD
New treatment option for Pulmonary Hypertension
Official title Continuous Effect Of Rehabilitation Training On Pulmonary Arterial Hypertension Patients
ClinicalTrials.gov ID: NCT07149935
What this study is testing
- What it's testing
- This multicenter, open label, double-arm study aims at investigating the the continuous effect of long-Term rehabilitation training on clinical improvement(ITTCI) and cardiopulmonary function in pulmonary arterial hypertension patients
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 75
You may be able to join if
- Patients who suffered from pre-capillary PAH (mPAP ≥ 20 mmHg, PVR \> 2 Woods unit, PAWP ≤ 15 mmHg) confirmed by right heart catheterisation.
- Patients who are in the status of WHO-FC I-III.
- Patients between 18 and 75 years old
- Female people are not pregnant.
- Patients are treated with PAH-targeted drugs and are in a stable state and there is no progress of disease).
You likely can't join if
- Patients with the following diseases or symptoms:
- Pulmonary vascular occlusive disease
- Respiratory diseases
- Ischaemic heart disease, complex congenital heart disease (e.g., tetralogy of Fallot, etc.), cardiomyopathy, valvular disease
- Active liver disease
- Severe kidney disease
See the full eligibility criteria
- Patients who suffered from pre-capillary PAH (mPAP ≥ 20 mmHg, PVR \> 2 Woods unit, PAWP ≤ 15 mmHg) confirmed by right heart catheterisation.
- Patients who are in the status of WHO-FC I-III.
- Patients between 18 and 75 years old
- Female people are not pregnant.
- Patients are treated with PAH-targeted drugs and are in a stable state and there is no progress of disease).
- Patients have not received exercise rehabilitation training within six months.
- Patients with the following diseases or symptoms:
- Pulmonary vascular occlusive disease
- Respiratory diseases
- Ischaemic heart disease, complex congenital heart disease (e.g., tetralogy of Fallot, etc.), cardiomyopathy, valvular disease
- Active liver disease
- Severe kidney disease
- Motor disorders (e.g. lower limb fracture, ataxia, etc.)
- Malignant tumour diseases
- Physical disability
- Hb ≤ 80g / L
- Systolic blood pressure ≤85mmHg
- History of syncope within 3 months
- History of supraventricular or ventricular arrhythmia at rest within 3 months.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 75 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.